Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor (clinicaltrials.gov) - Sep 23, 2026 - P3 | N=81 | Recruiting | Sponsor: Washington University School of Medicine | Trial completion date: Feb 2028 ➔ Feb 2029 | Trial primary completion date: Feb 2028 ➔ Feb 2029
Monotherapy • Trial completion date • Trial primary completion date • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CDKN2A
|